Jpmorgan Chase & CO Intra Cellular Therapies, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 3,435,232 shares of ITCI stock, worth $259 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
3,435,232
Previous 1,755,948
95.63%
Holding current value
$259 Million
Previous $122 Million
93.63%
% of portfolio
0.02%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding ITCI
# of Institutions
400Shares Held
87.2MCall Options Held
309KPut Options Held
302K-
Vanguard Group Inc Valley Forge, PA9.61MShares$724 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$477 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.72MShares$280 Million1.37% of portfolio
-
Avoro Capital Advisors LLC New York, NY3MShares$226 Million2.8% of portfolio
-
Invesco Ltd. Atlanta, GA2.94MShares$222 Million0.04% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $7.12B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...